Peptide Initiative
Back to Relaxin-2 (Serelaxin)

Clinical trials

Every registered trial of Relaxin-2 (Serelaxin)

16 studies.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Very little human research on Relaxin-2 (Serelaxin) has been registered.
  • 16 registered studies in total.
  • None are currently enrolling — this research has already happened.

What kind of research

  • 16 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 10,978 people took part in those.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 16 of 16 trials for Relaxin-2 (Serelaxin).

  • NCT02669875 Phase 2Completed15 enrolled2017

    Serelaxin To Lower Portal Pressure

    University of Edinburgh

    Liver Cirrhosis · Hypertension, Portal

  • NCT02625922 Phase 2Terminated26 enrolled2016

    Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

    Novartis Pharmaceuticals

    Chronic Heart Failure

  • NCT02151383 Phase 2Terminated12 enrolled2014

    Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

    Novartis Pharmaceuticals

    Acute Heart Failure

  • NCT01982292 Phase 2Completed321 enrolled2014

    Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

    Novartis Pharmaceuticals

    Chronic Heart Failure

  • NCT02007720 Phase 3Terminated876 enrolled2014

    Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

    Novartis Pharmaceuticals

    Acute Heart Failure

  • NCT01979614 Phase 2Completed58 enrolled2014

    Study of the Vascular Effects of Serelaxin

    Novartis Pharmaceuticals

    Coronary Artery Disease

  • NCT02064868 Phase 3Terminated2,666 enrolled2014

    Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

    Novartis Pharmaceuticals

    Acute Heart Failure (AHF)

  • NCT02002702 Phase 2Completed46 enrolled2014

    Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients

    Novartis Pharmaceuticals

    Acute Heart Failure

  • NCT01870778 Phase 3Completed6,600 enrolled2013

    Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

    Novartis Pharmaceuticals

    Acute Heart Failure

  • NCT01875523 Phase 1Completed36 enrolled2013

    PK of Serelaxin in Severe Renal Impairment and ESRD

    Novartis Pharmaceuticals

    Renal Failure, Chronic · End-Stage Renal Disease

  • NCT01566630 Phase 2Terminated3 enrolled2013

    Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

    Novartis Pharmaceuticals

    Pre-eclampsia

  • NCT01640964 Phase 2Completed47 enrolled2013

    An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

    Novartis Pharmaceuticals

    Compensated Cirrhosis and Portal Hypertension

  • NCT01543854 Phase 2Completed71 enrolled2012

    Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

    Novartis Pharmaceuticals

    Acute Heart Failure

  • NCT01546532 Phase 2Completed118 enrolled2012

    Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

    Novartis Pharmaceuticals

    Chronic Heart Failure (CHF)

  • NCT00406575 Phase 2Terminated11 enrolled2006

    Recombinant Human Relaxin for the Treatment of Decompensated CHF

    Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    Congestive Heart Failure (CHF)

  • NCT00259103 Phase 2Completed72 enrolled2005

    Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

    Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    Labor, Induced

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Relaxin-2 (Serelaxin) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.